SlideShare une entreprise Scribd logo
INFECTIVE ENDOCARDITIS
Prepared by KUTOSI Joseph (MBCh.B–V)
Kampala international university-WC.
EXPECTATIONS OF THIS PRESENTATION
• Introduction ( definition and important notes )
• Epidemiology
• Risk factors
• Etiology and pathophysiology
• Signs and symptoms
• Diagnosis [ Modified dukes criteria and ESC- criteria)
• Management and prognosis.
• Prevention.
• Q & A session and supplements.
INTRODUCTION
• Infective endocarditis is infection of the endocardium, usually with bacteria (commonly, streptococci
or staphylococci) or fungi.
• It may cause fever, heart murmurs, petechiae, anemia, embolic phenomena, and endocardial
vegetations.
• Vegetations may result in valvular incompetence or obstruction, myocardial abscess, or mycotic
aneurysm.
• Diagnosis requires demonstration of microorganisms in blood and usually echocardiography.
• Treatment consists of prolonged antimicrobial treatment and sometimes surgery.
INTRODUCTION
• Endocarditis usually refers to infection of the endocardium (ie, infective
endocarditis).
• The term can also include noninfective endocarditis, in which sterile
platelet and fibrin thrombi form on cardiac valves and adjacent
endocardium.
• Noninfective endocarditis sometimes leads to infective endocarditis.
• Both can result in embolization and impaired cardiac function.
• The diagnosis of infective endocarditis is usually based on a
constellation of clinical findings rather than a single definitive test result.
EPIDEMIOLOGY OF INFECTIVE
ENDOCARDITIS
• In the United States, the incidence of IE is approximately 12.7 cases per
100,000 persons per year.
• The incidence of IE in other countries is similar to that in the United States.
• The proportion of patients with intracardiac devices has increased from
13.3% to 18.9%, whereas the proportion of cases with a background of HIV
infection or IV drug abuse has fallen.
• The mean age of patients has increased from 58.6 to 60.8 years and
continues to rise; more than 50% of patients are older than 50 years
• Infective endocarditis is 3 times more common in males than in females. It
exhibits no racial predilection.
Adapted from medscape mobile app [latest version Feb 2023].
EPIDEMIOLOGY OF INFECTIVE
ENDOCARDITIS IN AFRICA: A SYSTEMATIC
REVIEW AND META-ANALYSIS. 2022.
• Rheumatic heart disease was the most common risk factor for infective endocarditis in adults - 52%,
whereas congenital heart disease was the most common risk factor for infective endocarditis in
children (44·7%)
• Microbiological testing (mostly blood cultures) was positive in 48·6% of patients with infective
endocarditis, with Staphylococcus species 41.3% and Streptococcus species (34·0% ) the most
commonly identified microorganisms.
• The pooled rate of surgical treatment of infective endocarditis was 49·1%.
• The pooled in-hospital mortality rate was 22·6%.
• Other frequent complications included heart failure (47·0%), acute kidney injury (22·8), and embolic
events (31·1% ).
Adapted from https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00400-9/fulltext
RISK FACTORS OF INFECTIVE
ENDOCARDITIS
• Infective endocarditis can occur at any age.
• Men are affected about twice as often as women.
• Incidence of infection and mortality increase with increasing age.
• Patients who use illicit intravenous drugs, immunocompromised patients, patients with prosthetic
heart valves and other intracardiac devices are at highest risk.
• There is also an increased risk in patients with indwelling intravascular catheters.
ETIOLOGY AND PATHOPHYSIOLOGY
• The normal heart is relatively resistant to infection. Bacteria and fungi do
not easily adhere to the endocardial surface, and constant blood flow
helps prevent them from settling on endocardial structures. Thus, 2
factors are typically required for endocarditis:
1.A predisposing abnormality of the endocardium
2.Microorganisms in the bloodstream (bacteremia)
Important to note that Massive bacteremia or particularly virulent
microorganisms (eg, Staphylococcus aureus) cause endocarditis on normal
valves.
ETIOLOGY AND PATHOPHYSIOLOGY OF
INFECTIVE ENDOCARDITIS
The disease develops in 3 stages:
Bacteremia: Microorganisms are present in the blood
Adhesion: The microorganism adheres to abnormal or damaged
endothelium via surface adhesions
Colonization: Proliferation of the organism together with inflammation,
leading to a mature vegetation
Many of the causative microorganisms produce polysaccharide biofilms
that shield them from host immune defences and impede antibiotic
penetration.
ETIOLOGY AND PATHOPHYSIOLOGY OF
INFECTIVE ENDOCARDITIS
• The normal heart is relatively resistant to infection. Bacteria and fungi do
not easily adhere to the endocardial surface, and constant blood flow
helps prevent them from settling on endocardial structures.
Two factors are typically required for endocarditis:
1. A predisposing abnormality of the endocardium
2. Microorganisms in the bloodstream (bacteremia)
Massive bacteremia or particularly virulent microorganisms (eg, S. aureus)
cause endocarditis on normal valves.
ETIOLOGY AND PATHOPHYSIOLOGY
[ENDOCARDIAL FACTORS]
• Usually involves the heart valves
• Congenital heart defects, rheumatic valvular
disease, bicuspid aortic valves, calcific aortic
valves, mitral valve prolapse, hypertrophic
cardiomyopathy, and prior endocarditis.
• Prosthetic valves and other intracardiac
devices.
• Occasionally, mural thrombi, ventricular septal
defects, and patent ductus arteriosus sites
become infected.
• The nidus for infection is usually a sterile fibrin-
platelet vegetation formed when damaged
endothelial cells release tissue factor.
• Infective endocarditis occurs most often on the
left side (eg, mitral or aortic valve).
• About 10 to 20% of cases are right-sided
(tricuspid or pulmonic valve).
• Patients who use illicit intravenous drugs have
a much higher incidence of right-sided
endocarditis (about 30 to 70%
ETIOLOGY AND PATHOPHYSIOLOGY OF
INFECTIVE ENDOCARDITIS
The disease develops in 3 stages:
1.Bacteremia: Microorganisms are present in the
blood
2. Adhesion: The microorganism adheres to
abnormal or damaged endothelium via surface
adhesions
3. Colonization: Proliferation of the organism
together with inflammation, leading to a mature
vegetation
Many of the causative microorganisms produce
polysaccharide biofilms that shield them from host
immune defences and impede antibiotic
penetration.
• Causative organisms vary by site of
infection, source of bacteremia, and host
risk factors (eg, IV illicit drug use), but
overall, streptococci and Staphylococcus
aureus cause 80 to 90% of cases.
• Enterococci, gram-negative bacilli,
HACEK organisms (Haemophilus
species, Actinobacillus
actinomycetemcomitans,
Cardiobacterium hominis, Eikenella
corrodens, and Kingella kingae), and
fungi cause most of the rest.
ETIOLOGY AND PATHOPHYSIOLOGY OF INFECTIVE
ENDOCARDITIS
Local consequences.
• Myocardial abscesses with tissue destruction and
sometimes conduction system abnormalities (usually
with low septal abscesses)
• Sudden, severe valvular regurgitation, causing heart
failure and death (usually due to mitral or aortic valve
lesions)
• Aortitis due to contiguous spread of infection
• Prosthetic valve infections are particularly likely to
involve valve ring abscesses, obstructing vegetations,
myocardial abscesses, and mycotic aneurysms
manifested by valve obstruction, dehiscence, and
conduction disturbances.
Systemic consequences
• Systemic consequences of endocarditis are primarily due
to
• Embolization of infected material from the heart valve
• Immune-mediated phenomena (primarily in chronic
infection)
• Right-sided lesions produce septic pulmonary emboli,
resulting in pulmonary infarction, pneumonia, or
empyema.
• Left-sided lesions may embolize to any tissue,
particularly the kidneys, spleen, and central nervous
system.
• Mycotic aneurysms can form in any major artery.
• Cutaneous and retinal emboli are common.
• Diffuse glomerulonephritis may result from immune
complex deposition.
CLASSIFICATION OF INFECTIVE
ENDOCARDITIS
• Infective endocarditis may have an indolent, subacute course or a more
acute, fulminant course with greater potential for rapid decompensation.
• Classification is based on this and wether or not there is a prothethis, i.e
1. Sub acute Bacterial endocarditis
2. Acute bacterial endocarditis
3. Prosthetic valve endocarditis
SUBACUTE BACTERIAL ENDOCARDITIS
(SBE).
• Although aggressive, usually develops insidiously and progresses slowly
(ie, over weeks to months).
• Often, no source of infection or portal of entry is evident. SBE is caused
most commonly by streptococci (especially viridans, microaerophilic,
anaerobic, and nonenterococcal group D streptococci and enterococci).
• Less commonly by S. aureus, Staphylococcus epidermidis, Gemella
morbillorum, Abiotrophia defectiva (formerly, Streptococcus defectivus),
Granulicatella species, and fastidious Haemophilus species.
• SBE often develops on abnormal valves after asymptomatic bacteremia
due to periodontal, gastrointestinal, or genitourinary infections.
ACUTE BACTERIAL ENDOCARDITIS (ABE)
• Acute Bacterial endocarditis usually develops abruptly and progresses
rapidly (ie, over days).
• A source of infection or portal of entry is often evident.
• When bacteria are virulent or bacterial exposure is massive, ABE can
affect normal valves.
• It is usually caused by S. aureus, group A hemolytic streptococci,
pneumococci, or gonococci.
PROSTHETIC VALVULAR ENDOCARDITIS
(PVE)
• Develops in 2 to 3% of patients within 1 year after valve replacement and in 0.5%/year
thereafter.
• It is more common after aortic than after mitral valve replacement and affects
mechanical and bioprosthetic valves equally.
• Early-onset infections (< 2 months after surgery) are caused mainly by contamination
during surgery with antimicrobial-resistant bacteria (eg, S. epidermidis, diphtheroids,
coliform bacilli) or by fungi (eg, Candida species, Aspergillus species).
• Late-onset infections are caused mainly by contamination with low-virulence
organisms during surgery or by transient asymptomatic bacteremias, most often with
streptococci; S. epidermidis; diphtheroids; and the fastidious gram-negative bacilli,
Haemophilus species, Actinobacillus actinomycetemcomitans, and Cardiobacterium
hominis.
TYPES OF INFECTIVE ENDOCARDITIS
• Endocarditis has evolved into several variations, keeping it near the top
of the list of diseases that must not be misdiagnosed or overlooked.
• Endocarditis can be broken down into the following categories
1. Native valve endocarditis (NVE), acute and subacute
2. Prosthetic valve endocarditis (PVE), early and late
3. Intravenous drug abuse (IVDA) endocarditis.
4. Other terms commonly used to classify types of IE include pacemaker
IE and nosocomial IE (NIE)
SIGNS AND SYMPTOMS OF INFECTIVE
ENDOCARDITIS
• Symptoms and signs vary based on the classification but are usually
nonspecific.
In Sub acute bacterial endocarditis
Initially, symptoms of SBE are vague.
• low-grade fever (< 39° C), night sweats, fatigability, malaise, and weight loss.
• Chills and arthralgias may occur.
Symptoms and signs of valvular insufficiency may be a first clue.
• Initially, ≤ 15% of patients have fever or a murmur, but eventually almost all
develop both.
• Physical examination may be normal or include pallor, fever, change in a
preexisting murmur or development of a new regurgitant murmur, and
tachycardia.
SIGNS AND SYMPTOMS
• Retinal emboli can cause round or oval hemorrhagic retinal lesions with small white
centers (Roth spots).
• Cutaneous manifestations include petechiae (on the upper trunk, conjunctivae,
mucous membranes, and distal extremities), painful erythematous subcutaneous
nodules on or near the tips of digits (Osler nodes), nontender hemorrhagic macules or
papules on the palms or soles (Janeway lesions), and splinter hemorrhages under the
nails.
• About 35% of patients have central nervous system (CNS) effects, including transient
ischemic attacks, stroke, toxic encephalopathy (due to infective microemboli), and, if a
mycotic CNS aneurysm ruptures, brain abscess and subarachnoid hemorrhage.
• Renal emboli may cause flank pain and, rarely, gross hematuria.
• Splenic emboli may cause left upper quadrant pain. Prolonged infection may cause
splenomegaly or clubbing of fingers and toes.
SIGNS AND SYMPTOMS
Acute bacterial endocarditis and prosthetic valvular endocarditis.
• Symptoms and signs of acute bacterial endocarditis and prosthetic valvular
endocarditis are similar to those of subacute bacterial endocarditis, but the course is
more rapid.
• Fever is almost always present initially, and patients appear toxic; sometimes septic
shock develops.
• Heart murmur is present initially in about 50 to 80% and eventually in > 90%.
• Rarely, purulent meningitis occurs.
Right-sided endocarditis
• Septic pulmonary emboli may cause cough, pleuritic chest pain, and sometimes
hemoptysis. A murmur of tricuspid regurgitation is typical.
OSLER NODES AND JANEWAY LESIONS
OSLER NODES , JANEWAY LESIONS AND
SPLINTER HEMORRHAGES
OCULAR MANIFESTATION OF
INFFECTIVE ENDOCARDITIS.
COMPLICATIONS OF INFECTIVE
ENDOCARDITIS
• Myocardial infarction, pericarditis, cardiac arrhythmia
• Cardiac valvular insufficiency
• Congestive heart failure
• Sinus of Valsalva aneurysm(an abnormal dilatation of the aortic root located between the aortic valve
annulus and the sinotubular junction)
• Aortic root or myocardial abscesses
• Arterial emboli, infarcts, mycotic aneurysms
• Arthritis, myositis
• Glomerulonephritis, acute renal failure
• Stroke syndromes
• Mesenteric or splenic abscess or infarct
DIAGNOSIS OF INFECTIVE
ENDOCARDITIS
• Because symptoms and signs are nonspecific, vary greatly, and may
develop insidiously, diagnosis requires a high index of suspicion.
• Endocarditis should be suspected in patients with fever and no obvious
source of infection, particularly if a heart murmur is present.
Diagnosis involves;
1. Blood culture
2. Echocardiography and sometimes other imaging modalities
3. Clinical criteria
BLOOD CULTURES
• Identification of the organism and its antimicrobial susceptibility is vital to guide
treatment.
• Three ( 3 ) blood samples for culture (20-mL each) should be obtained, ideally > 6
hours apart (if presentation suggests acute bacterial endocarditis, 2 cultures within the
first 1 to 2 hours).
• Each set of cultures should be obtained from a separate, fresh venipuncture site.
• When endocarditis is present and no prior antibiotic therapy was given, all 3 blood
cultures usually are positive because the bacteremia is continuous; at least one culture
is positive in 99%.
• Premature use of empiric antibiotic therapy should be avoided in patients with
acquired or congenital valvular or shunt lesions to avoid culture-negative endocarditis.
• If prior antimicrobial therapy was given, blood cultures should still be obtained, but
results may be negative.
OTHER LABORATORY INVESTIGATIONS
• Other than positive blood cultures, there are no specific laboratory
findings.
• Established infections often cause a normocytic-normochromic anemia,
elevated WBC , increased ESR, increased immun IG levels, the presence
of circulating immune complexes and RF's, but these findings are not
diagnostically helpful.
• Urinalysis often shows microscopic hematuria and, occasionally, red
blood cell casts, pyuria, or bacteriuria.
IMAGING STUDIES
• Transthoracic echocardiography (TTE) should be done initially and has
sensitivity of 50 to 90% and specificity > 90%. Transesophageal
echocardiography (TEE) can reveal vegetations too small to be seen on TTE
with a sensitivity of 90 to 100%.
• Transesophageal echocardiography should be done when
1. Patients have a prosthetic valve (where TTE sensitivity is limited)
2. Transthoracic echocardiogram is nondiagnostic
3. Diagnosis of infective endocarditis has been established clinically (done to
detect perforations, abscesses, and fistulas)
NOTE ; Serial TEE enables diagnosis of complications that evolve during
treatment, such as increasing vegetation size or abscess formation.
IMAGING STUDIES
• CT-Scan can fully define paravalvular abscesses and detect mycotic
aneurysms.
• Positron emission tomography (PET) scanning improves the sensitivity of the
modified Duke criteria without compromising specificity.
• PET scanning also detects extracardiac infection, such as septic emboli, and
is an emerging tool for the diagnosis of endocarditis originating in prosthetic
and intracardiac devices.
• CT and PET abnormalities are now included as major criteria in the European
guidelines.
• Routine brain imaging has been proposed because up to 60% of patients
have clinically silent lesions. It’s utility for prognosis and management is yet
to be defined.
DIAGNOSTIC CRITERIA
• Infective endocarditis is definitively diagnosed when microorganisms are
seen histologically in (or cultured from) endocardial vegetations
obtained during cardiac surgery, embolectomy, or autopsy.
• Because vegetations are not usually available for examination, there are
various clinical criteria for establishing a diagnosis.
• They include ;
1. Modified Duke Criteria —with a sensitivity and specificity > 90%, and
2. The European Society of Cardiology (ESC) 2015 modified criteria.
MODIFIED DUKES CRITERIA
Endocarditis is felt to be present in the following
conditions:
Direct evidence of endocarditis based upon
histological findings (a pathological criterion)
Positive Gram stain results or cultures of
specimens obtained from surgery or autopsy (a
pathological criterion)
-2 major clinical criteria
-1 major and any 3 minor clinical criteria
-5 minor clinical criteria
Possible endocarditis’ is defined by 1 major and 1
or 2 minor clinical criteria, OR 3 minor clinical
The diagnosis of endocarditis is ‘rejected’ in any
of the following cases:
- a firm alternate diagnosis is made
- clinical manifestations resolve after ≤4 days of
antibiotic therapy
- no pathological evidence of infective
endocarditis is found at surgery or autopsy after
antibiotic therapy for ≤4 days
- fail to meet criteria for for possible or definite
infective endocarditis
MODIFIED DUKES CRITERIA [MAJOR
AND MINORS]
THE EUROPEAN SOCIETY OF
CARDIOLOGY CRITERIA
• The ESC criteria are similar to the modified Duke criteria but include
expanded imaging results as major criteria as follows:
1. Vegetation, abscess, pseudoaneurysm, intracardiac fistula, valvular
perforation or aneurysm, or new partial dehiscence of prosthetic valve
identified by echocardiography
2. Abnormal activity around a prosthetic valve (implanted > 3 months
earlier) detected by PET/CT or single-photon emission computed
tomography (SPECT)/CT with radiolabeled leukocytes
3. Paravalvular lesions identified by cardiac
• The ESC also differs from the modified Duke minor criteria by specifying that
detecting silent vascular phenomena by imaging only is sufficient.
MANAGEMENT
• IV antibiotics.
• Sometimes valve debridement, repair, or replacement
• Dental evaluation and treatment.
• Removal of potential source of bacteremia.
• Withholding anticoagulation in patients with cerebral embolism
UGANDA CLINICAL GUIDELINES (UCG) ANTIBIOTICS FOR
INFECTIVE ENDOCARDITIS
Initial empirical antibiotic therapy
• Benzylpenicillin 5 MU IV every 6 hours for 4 weeks
• Plus gentamicin 1 mg/kg IV every 8 hours for 2 weeks.
If staphylococcus suspected, (acute onset) add:
• Cloxacillin IV 3 g every 6 hours.
If MRSA (Multi-Resistant Staphylococcus aureus).
• Vancomycin 500 mg IV every 6 hours for 6 weeks.
PROGNOSIS
Overall, the in-hospital mortality rate for endocarditis is 15 to 20%, with a 1-year mortality rate approaching 40%.
Untreated, infective endocarditis is always fatal. Even with treatment, death is more likely and the prognosis is generally poorer for
older people and people who have
• Infection with resistant organisms
• An underlying disorder
• A long delay in treatment
• Aortic valve or multiple valve involvement
• Large vegetations
• Polymicrobial bacteremia
• Prosthetic valve infections
• Mycotic aneurysms
• Valve ring abscess
• Major embolic events
PROGNOSIS
• Septic shock is more likely in patients with diabetes, acute kidney injury,
S. aureus infection, vegetation size > 15 mm, and signs of persistent
infection.
• The mortality rate for viridans streptococcal endocarditis without major
complications is < 10% but is virtually 100% for Aspergillus endocarditis
after prosthetic valve surgery.
• The prognosis is better with right-sided than left-sided endocarditis
because tricuspid valve dysfunction is tolerated better, systemic emboli
are absent, and right-sided S. aureus endocarditis responds better to
antimicrobial therapy.
PREVENTION OF INFECTIVE
ENDOCARDITIS
• Preventive dental examination and therapy before surgery to repair heart valves or congenital heart
lesions is recommended.
• Measures to reduce health care–acquired bacteremia aim to curb the rising incidence of iatrogenic
bacteremia and subsequent endocarditis are also recommended.
• During implantation of prosthetic devices, prophylaxis often involves use of amoxicillin/clavulanic acid.
• Dental and cutaneous hygiene is recommended for the general population but particularly for patients at
intermediate risk (those with native valve disease) and high-risk.
PREVENTION OF INFECTIVE
ENDOCARDITIS.
• Prosthetic heart valves, including transcatheter implanted prostheses
• Prosthetic material used for heart valve repair (eg, annuloplasty rings,
chords)
• Previous infective endocarditis
• Certain congenital heart diseases (CHD): Unrepaired cyanotic CHD
(including palliative shunts and conduits), completely repaired CHD
during the first 6 mo after surgery if prosthetic material or device was
used, repaired CHD that has residual defects at or adjacent to the site of
repair
• Heart transplant recipients with valvulopathy
LIBAN SACKS ENDOCARDITIS
• Non infection related endocarditis associated with Systemic lupus
erytheramatosus
• Antigen-antibody complexes.
• Affects mainly the mitral valve, but can affect both atrial and ventricular
endocardium.
THANK YOU NOTE AND REFERENCES
Thank you for paying attention, may you be able to prevent infective
endocarditis and efficiently manage patient presenting with the condition.
References
1.Davidsons
2. Uganda clinical guidelines (UCG)
3. Merck manuals (MSD) 2022.

Contenu connexe

Tendances

Infective endocarditis – an update
Infective endocarditis – an update Infective endocarditis – an update
Infective endocarditis – an update
Harshitha S
 
Ectopic Beats
Ectopic BeatsEctopic Beats
Ectopic Beats
Ayesha Bukhari
 
2015 ESC Guidelines on Infective Endocarditis ppt. by Dr Abhishek Rathore MD
2015 ESC Guidelines on Infective Endocarditis ppt. by Dr Abhishek Rathore MD2015 ESC Guidelines on Infective Endocarditis ppt. by Dr Abhishek Rathore MD
2015 ESC Guidelines on Infective Endocarditis ppt. by Dr Abhishek Rathore MD
drabhishekbabbu
 
Sepsis and septic shock
Sepsis and septic shockSepsis and septic shock
Sepsis and septic shock
mahadev deuja
 
Infective endocarditis
Infective endocarditisInfective endocarditis
Infective endocarditis
Mohamad Yaakub
 
Infective Endocarditis
Infective EndocarditisInfective Endocarditis
Infective Endocarditis
hospital
 
Infective endocarditis updated
Infective endocarditis updatedInfective endocarditis updated
Infective endocarditis updated
Tasneem Bashir • تسنيم بشير
 
Infective endocarditis
Infective endocarditisInfective endocarditis
Infective endocarditis
Abhinav Srivastava
 
Device associated hospital acquired infection (da hai)
Device associated hospital acquired infection (da hai)Device associated hospital acquired infection (da hai)
Device associated hospital acquired infection (da hai)
Central Govt, India
 
Infective Endocarditis and It's Surgical Management
Infective Endocarditis and It's Surgical ManagementInfective Endocarditis and It's Surgical Management
Infective Endocarditis and It's Surgical Management
Alireza Kashani
 
Infective endocarditis/ endocarditis
Infective endocarditis/ endocarditisInfective endocarditis/ endocarditis
Infective endocarditis/ endocarditis
SundaresanL
 
Myocardial infarction
Myocardial infarction Myocardial infarction
Myocardial infarction
Shams Rehan
 
Cns infections biplave nams
Cns infections biplave namsCns infections biplave nams
Cns infections biplave nams
biplave karki
 
Evaluation of syncope in adults
Evaluation of syncope in adultsEvaluation of syncope in adults
Evaluation of syncope in adults
Dr.Goutham Valapala
 
Acute rheumatic fever
Acute rheumatic feverAcute rheumatic fever
Acute rheumatic fever
Betelehem Tefera
 
15 ie
15 ie15 ie
Sepsis & Septic Shock
Sepsis & Septic ShockSepsis & Septic Shock
Sepsis & Septic Shock
Imhotep Virtual Medical School
 
ATRIAL FIBRILLATION
ATRIAL FIBRILLATIONATRIAL FIBRILLATION
ATRIAL FIBRILLATION
Best Doctors
 
Endocarditis.ppt
Endocarditis.pptEndocarditis.ppt
Endocarditis.ppt
JOICY45
 
Myocarditis.pptx
Myocarditis.pptxMyocarditis.pptx
Myocarditis.pptx
Safoora Qureshi
 

Tendances (20)

Infective endocarditis – an update
Infective endocarditis – an update Infective endocarditis – an update
Infective endocarditis – an update
 
Ectopic Beats
Ectopic BeatsEctopic Beats
Ectopic Beats
 
2015 ESC Guidelines on Infective Endocarditis ppt. by Dr Abhishek Rathore MD
2015 ESC Guidelines on Infective Endocarditis ppt. by Dr Abhishek Rathore MD2015 ESC Guidelines on Infective Endocarditis ppt. by Dr Abhishek Rathore MD
2015 ESC Guidelines on Infective Endocarditis ppt. by Dr Abhishek Rathore MD
 
Sepsis and septic shock
Sepsis and septic shockSepsis and septic shock
Sepsis and septic shock
 
Infective endocarditis
Infective endocarditisInfective endocarditis
Infective endocarditis
 
Infective Endocarditis
Infective EndocarditisInfective Endocarditis
Infective Endocarditis
 
Infective endocarditis updated
Infective endocarditis updatedInfective endocarditis updated
Infective endocarditis updated
 
Infective endocarditis
Infective endocarditisInfective endocarditis
Infective endocarditis
 
Device associated hospital acquired infection (da hai)
Device associated hospital acquired infection (da hai)Device associated hospital acquired infection (da hai)
Device associated hospital acquired infection (da hai)
 
Infective Endocarditis and It's Surgical Management
Infective Endocarditis and It's Surgical ManagementInfective Endocarditis and It's Surgical Management
Infective Endocarditis and It's Surgical Management
 
Infective endocarditis/ endocarditis
Infective endocarditis/ endocarditisInfective endocarditis/ endocarditis
Infective endocarditis/ endocarditis
 
Myocardial infarction
Myocardial infarction Myocardial infarction
Myocardial infarction
 
Cns infections biplave nams
Cns infections biplave namsCns infections biplave nams
Cns infections biplave nams
 
Evaluation of syncope in adults
Evaluation of syncope in adultsEvaluation of syncope in adults
Evaluation of syncope in adults
 
Acute rheumatic fever
Acute rheumatic feverAcute rheumatic fever
Acute rheumatic fever
 
15 ie
15 ie15 ie
15 ie
 
Sepsis & Septic Shock
Sepsis & Septic ShockSepsis & Septic Shock
Sepsis & Septic Shock
 
ATRIAL FIBRILLATION
ATRIAL FIBRILLATIONATRIAL FIBRILLATION
ATRIAL FIBRILLATION
 
Endocarditis.ppt
Endocarditis.pptEndocarditis.ppt
Endocarditis.ppt
 
Myocarditis.pptx
Myocarditis.pptxMyocarditis.pptx
Myocarditis.pptx
 

Similaire à infective endocarditis - KUTOSI Joseph.pptx

INFECTIVE ENDOCARDITIS.pptx
INFECTIVE ENDOCARDITIS.pptxINFECTIVE ENDOCARDITIS.pptx
INFECTIVE ENDOCARDITIS.pptx
1901600146
 
Infective endocarditis
Infective endocarditisInfective endocarditis
Infective endocarditis
Suprakash Das
 
4_6030689835172236523.pptx
4_6030689835172236523.pptx4_6030689835172236523.pptx
4_6030689835172236523.pptx
JibrilAliSe
 
Bacterial endocarditis
Bacterial  endocarditisBacterial  endocarditis
Bacterial endocarditis
Sakina Musa
 
Blood stream infections- clinical microbiology
Blood stream infections- clinical microbiologyBlood stream infections- clinical microbiology
Blood stream infections- clinical microbiology
Sijo A
 
Infective endocarditis for urse student.pptx
Infective endocarditis for urse student.pptxInfective endocarditis for urse student.pptx
Infective endocarditis for urse student.pptx
mekulecture
 
Endocarditis april 2018
Endocarditis  april 2018Endocarditis  april 2018
Endocarditis april 2018
Meher Rizvi
 
Infective endocarditis
Infective endocarditisInfective endocarditis
Infective endocarditis
Himanshu Samaiya
 
Infective Endocarditis
Infective EndocarditisInfective Endocarditis
Infective Endocarditis
Sameh Abdel-ghany
 
INFECTIVE ENDOCARDITIS.pptx
INFECTIVE ENDOCARDITIS.pptxINFECTIVE ENDOCARDITIS.pptx
INFECTIVE ENDOCARDITIS.pptx
BadarJamal4
 
Meningitis
MeningitisMeningitis
Meningitis
Dr Arathy R Nath
 
Infective endocarditis FINAL.pptx
Infective endocarditis FINAL.pptxInfective endocarditis FINAL.pptx
Infective endocarditis FINAL.pptx
RashiSrivastava62
 
Infective endocarditis.pptx
Infective endocarditis.pptxInfective endocarditis.pptx
Infective endocarditis.pptx
aishanteme
 
infectiveendocarditis-july2015-190917173103.ppt
infectiveendocarditis-july2015-190917173103.pptinfectiveendocarditis-july2015-190917173103.ppt
infectiveendocarditis-july2015-190917173103.ppt
jenishJebadurai1
 
ENDOCARDITIS
ENDOCARDITIS ENDOCARDITIS
ENDOCARDITIS
NiranjanaES
 
Microbes affecting the Cardiovas Syst.pptx
Microbes affecting the Cardiovas Syst.pptxMicrobes affecting the Cardiovas Syst.pptx
Microbes affecting the Cardiovas Syst.pptx
SuhaybCumar2
 
Endocarditis
EndocarditisEndocarditis
Endocarditis
adolescent4u
 
infectiveendocarditis-july2015-190917173103.pdf
infectiveendocarditis-july2015-190917173103.pdfinfectiveendocarditis-july2015-190917173103.pdf
infectiveendocarditis-july2015-190917173103.pdf
HaroonButt17
 
Infective endocarditis
Infective endocarditis Infective endocarditis
Infective endocarditis
ikramdr01
 
Infective Endocarditis (IE) Lecture pptx
Infective Endocarditis (IE) Lecture pptxInfective Endocarditis (IE) Lecture pptx
Infective Endocarditis (IE) Lecture pptx
Shashi Prakash
 

Similaire à infective endocarditis - KUTOSI Joseph.pptx (20)

INFECTIVE ENDOCARDITIS.pptx
INFECTIVE ENDOCARDITIS.pptxINFECTIVE ENDOCARDITIS.pptx
INFECTIVE ENDOCARDITIS.pptx
 
Infective endocarditis
Infective endocarditisInfective endocarditis
Infective endocarditis
 
4_6030689835172236523.pptx
4_6030689835172236523.pptx4_6030689835172236523.pptx
4_6030689835172236523.pptx
 
Bacterial endocarditis
Bacterial  endocarditisBacterial  endocarditis
Bacterial endocarditis
 
Blood stream infections- clinical microbiology
Blood stream infections- clinical microbiologyBlood stream infections- clinical microbiology
Blood stream infections- clinical microbiology
 
Infective endocarditis for urse student.pptx
Infective endocarditis for urse student.pptxInfective endocarditis for urse student.pptx
Infective endocarditis for urse student.pptx
 
Endocarditis april 2018
Endocarditis  april 2018Endocarditis  april 2018
Endocarditis april 2018
 
Infective endocarditis
Infective endocarditisInfective endocarditis
Infective endocarditis
 
Infective Endocarditis
Infective EndocarditisInfective Endocarditis
Infective Endocarditis
 
INFECTIVE ENDOCARDITIS.pptx
INFECTIVE ENDOCARDITIS.pptxINFECTIVE ENDOCARDITIS.pptx
INFECTIVE ENDOCARDITIS.pptx
 
Meningitis
MeningitisMeningitis
Meningitis
 
Infective endocarditis FINAL.pptx
Infective endocarditis FINAL.pptxInfective endocarditis FINAL.pptx
Infective endocarditis FINAL.pptx
 
Infective endocarditis.pptx
Infective endocarditis.pptxInfective endocarditis.pptx
Infective endocarditis.pptx
 
infectiveendocarditis-july2015-190917173103.ppt
infectiveendocarditis-july2015-190917173103.pptinfectiveendocarditis-july2015-190917173103.ppt
infectiveendocarditis-july2015-190917173103.ppt
 
ENDOCARDITIS
ENDOCARDITIS ENDOCARDITIS
ENDOCARDITIS
 
Microbes affecting the Cardiovas Syst.pptx
Microbes affecting the Cardiovas Syst.pptxMicrobes affecting the Cardiovas Syst.pptx
Microbes affecting the Cardiovas Syst.pptx
 
Endocarditis
EndocarditisEndocarditis
Endocarditis
 
infectiveendocarditis-july2015-190917173103.pdf
infectiveendocarditis-july2015-190917173103.pdfinfectiveendocarditis-july2015-190917173103.pdf
infectiveendocarditis-july2015-190917173103.pdf
 
Infective endocarditis
Infective endocarditis Infective endocarditis
Infective endocarditis
 
Infective Endocarditis (IE) Lecture pptx
Infective Endocarditis (IE) Lecture pptxInfective Endocarditis (IE) Lecture pptx
Infective Endocarditis (IE) Lecture pptx
 

Dernier

Top-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India ListTop-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India List
SwisschemDerma
 
OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1
KafrELShiekh University
 
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
FFragrant
 
Identifying Major Symptoms of Slip Disc.
 Identifying Major Symptoms of Slip Disc. Identifying Major Symptoms of Slip Disc.
Identifying Major Symptoms of Slip Disc.
Gokuldas Hospital
 
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
19various
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Oleg Kshivets
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
rishi2789
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
AyeshaZaid1
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Ayurveda ForAll
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
rishi2789
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Holistified Wellness
 
Journal Article Review on Rasamanikya
Journal Article Review on RasamanikyaJournal Article Review on Rasamanikya
Journal Article Review on Rasamanikya
Dr. Jyothirmai Paindla
 
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
bkling
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
rishi2789
 
Diabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatmentDiabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatment
arahmanzai5
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
Jim Jacob Roy
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
HongBiThi1
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
Health Advances
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd...
TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd...TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd...
TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd...
Donc Test
 

Dernier (20)

Top-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India ListTop-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India List
 
OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1
 
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
 
Identifying Major Symptoms of Slip Disc.
 Identifying Major Symptoms of Slip Disc. Identifying Major Symptoms of Slip Disc.
Identifying Major Symptoms of Slip Disc.
 
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
 
Journal Article Review on Rasamanikya
Journal Article Review on RasamanikyaJournal Article Review on Rasamanikya
Journal Article Review on Rasamanikya
 
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
 
Diabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatmentDiabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatment
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
 
TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd...
TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd...TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd...
TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd...
 

infective endocarditis - KUTOSI Joseph.pptx

  • 1. INFECTIVE ENDOCARDITIS Prepared by KUTOSI Joseph (MBCh.B–V) Kampala international university-WC.
  • 2. EXPECTATIONS OF THIS PRESENTATION • Introduction ( definition and important notes ) • Epidemiology • Risk factors • Etiology and pathophysiology • Signs and symptoms • Diagnosis [ Modified dukes criteria and ESC- criteria) • Management and prognosis. • Prevention. • Q & A session and supplements.
  • 3. INTRODUCTION • Infective endocarditis is infection of the endocardium, usually with bacteria (commonly, streptococci or staphylococci) or fungi. • It may cause fever, heart murmurs, petechiae, anemia, embolic phenomena, and endocardial vegetations. • Vegetations may result in valvular incompetence or obstruction, myocardial abscess, or mycotic aneurysm. • Diagnosis requires demonstration of microorganisms in blood and usually echocardiography. • Treatment consists of prolonged antimicrobial treatment and sometimes surgery.
  • 4. INTRODUCTION • Endocarditis usually refers to infection of the endocardium (ie, infective endocarditis). • The term can also include noninfective endocarditis, in which sterile platelet and fibrin thrombi form on cardiac valves and adjacent endocardium. • Noninfective endocarditis sometimes leads to infective endocarditis. • Both can result in embolization and impaired cardiac function. • The diagnosis of infective endocarditis is usually based on a constellation of clinical findings rather than a single definitive test result.
  • 5. EPIDEMIOLOGY OF INFECTIVE ENDOCARDITIS • In the United States, the incidence of IE is approximately 12.7 cases per 100,000 persons per year. • The incidence of IE in other countries is similar to that in the United States. • The proportion of patients with intracardiac devices has increased from 13.3% to 18.9%, whereas the proportion of cases with a background of HIV infection or IV drug abuse has fallen. • The mean age of patients has increased from 58.6 to 60.8 years and continues to rise; more than 50% of patients are older than 50 years • Infective endocarditis is 3 times more common in males than in females. It exhibits no racial predilection. Adapted from medscape mobile app [latest version Feb 2023].
  • 6. EPIDEMIOLOGY OF INFECTIVE ENDOCARDITIS IN AFRICA: A SYSTEMATIC REVIEW AND META-ANALYSIS. 2022. • Rheumatic heart disease was the most common risk factor for infective endocarditis in adults - 52%, whereas congenital heart disease was the most common risk factor for infective endocarditis in children (44·7%) • Microbiological testing (mostly blood cultures) was positive in 48·6% of patients with infective endocarditis, with Staphylococcus species 41.3% and Streptococcus species (34·0% ) the most commonly identified microorganisms. • The pooled rate of surgical treatment of infective endocarditis was 49·1%. • The pooled in-hospital mortality rate was 22·6%. • Other frequent complications included heart failure (47·0%), acute kidney injury (22·8), and embolic events (31·1% ). Adapted from https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00400-9/fulltext
  • 7. RISK FACTORS OF INFECTIVE ENDOCARDITIS • Infective endocarditis can occur at any age. • Men are affected about twice as often as women. • Incidence of infection and mortality increase with increasing age. • Patients who use illicit intravenous drugs, immunocompromised patients, patients with prosthetic heart valves and other intracardiac devices are at highest risk. • There is also an increased risk in patients with indwelling intravascular catheters.
  • 8. ETIOLOGY AND PATHOPHYSIOLOGY • The normal heart is relatively resistant to infection. Bacteria and fungi do not easily adhere to the endocardial surface, and constant blood flow helps prevent them from settling on endocardial structures. Thus, 2 factors are typically required for endocarditis: 1.A predisposing abnormality of the endocardium 2.Microorganisms in the bloodstream (bacteremia) Important to note that Massive bacteremia or particularly virulent microorganisms (eg, Staphylococcus aureus) cause endocarditis on normal valves.
  • 9. ETIOLOGY AND PATHOPHYSIOLOGY OF INFECTIVE ENDOCARDITIS The disease develops in 3 stages: Bacteremia: Microorganisms are present in the blood Adhesion: The microorganism adheres to abnormal or damaged endothelium via surface adhesions Colonization: Proliferation of the organism together with inflammation, leading to a mature vegetation Many of the causative microorganisms produce polysaccharide biofilms that shield them from host immune defences and impede antibiotic penetration.
  • 10. ETIOLOGY AND PATHOPHYSIOLOGY OF INFECTIVE ENDOCARDITIS • The normal heart is relatively resistant to infection. Bacteria and fungi do not easily adhere to the endocardial surface, and constant blood flow helps prevent them from settling on endocardial structures. Two factors are typically required for endocarditis: 1. A predisposing abnormality of the endocardium 2. Microorganisms in the bloodstream (bacteremia) Massive bacteremia or particularly virulent microorganisms (eg, S. aureus) cause endocarditis on normal valves.
  • 11. ETIOLOGY AND PATHOPHYSIOLOGY [ENDOCARDIAL FACTORS] • Usually involves the heart valves • Congenital heart defects, rheumatic valvular disease, bicuspid aortic valves, calcific aortic valves, mitral valve prolapse, hypertrophic cardiomyopathy, and prior endocarditis. • Prosthetic valves and other intracardiac devices. • Occasionally, mural thrombi, ventricular septal defects, and patent ductus arteriosus sites become infected. • The nidus for infection is usually a sterile fibrin- platelet vegetation formed when damaged endothelial cells release tissue factor. • Infective endocarditis occurs most often on the left side (eg, mitral or aortic valve). • About 10 to 20% of cases are right-sided (tricuspid or pulmonic valve). • Patients who use illicit intravenous drugs have a much higher incidence of right-sided endocarditis (about 30 to 70%
  • 12. ETIOLOGY AND PATHOPHYSIOLOGY OF INFECTIVE ENDOCARDITIS The disease develops in 3 stages: 1.Bacteremia: Microorganisms are present in the blood 2. Adhesion: The microorganism adheres to abnormal or damaged endothelium via surface adhesions 3. Colonization: Proliferation of the organism together with inflammation, leading to a mature vegetation Many of the causative microorganisms produce polysaccharide biofilms that shield them from host immune defences and impede antibiotic penetration. • Causative organisms vary by site of infection, source of bacteremia, and host risk factors (eg, IV illicit drug use), but overall, streptococci and Staphylococcus aureus cause 80 to 90% of cases. • Enterococci, gram-negative bacilli, HACEK organisms (Haemophilus species, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae), and fungi cause most of the rest.
  • 13. ETIOLOGY AND PATHOPHYSIOLOGY OF INFECTIVE ENDOCARDITIS Local consequences. • Myocardial abscesses with tissue destruction and sometimes conduction system abnormalities (usually with low septal abscesses) • Sudden, severe valvular regurgitation, causing heart failure and death (usually due to mitral or aortic valve lesions) • Aortitis due to contiguous spread of infection • Prosthetic valve infections are particularly likely to involve valve ring abscesses, obstructing vegetations, myocardial abscesses, and mycotic aneurysms manifested by valve obstruction, dehiscence, and conduction disturbances. Systemic consequences • Systemic consequences of endocarditis are primarily due to • Embolization of infected material from the heart valve • Immune-mediated phenomena (primarily in chronic infection) • Right-sided lesions produce septic pulmonary emboli, resulting in pulmonary infarction, pneumonia, or empyema. • Left-sided lesions may embolize to any tissue, particularly the kidneys, spleen, and central nervous system. • Mycotic aneurysms can form in any major artery. • Cutaneous and retinal emboli are common. • Diffuse glomerulonephritis may result from immune complex deposition.
  • 14. CLASSIFICATION OF INFECTIVE ENDOCARDITIS • Infective endocarditis may have an indolent, subacute course or a more acute, fulminant course with greater potential for rapid decompensation. • Classification is based on this and wether or not there is a prothethis, i.e 1. Sub acute Bacterial endocarditis 2. Acute bacterial endocarditis 3. Prosthetic valve endocarditis
  • 15. SUBACUTE BACTERIAL ENDOCARDITIS (SBE). • Although aggressive, usually develops insidiously and progresses slowly (ie, over weeks to months). • Often, no source of infection or portal of entry is evident. SBE is caused most commonly by streptococci (especially viridans, microaerophilic, anaerobic, and nonenterococcal group D streptococci and enterococci). • Less commonly by S. aureus, Staphylococcus epidermidis, Gemella morbillorum, Abiotrophia defectiva (formerly, Streptococcus defectivus), Granulicatella species, and fastidious Haemophilus species. • SBE often develops on abnormal valves after asymptomatic bacteremia due to periodontal, gastrointestinal, or genitourinary infections.
  • 16. ACUTE BACTERIAL ENDOCARDITIS (ABE) • Acute Bacterial endocarditis usually develops abruptly and progresses rapidly (ie, over days). • A source of infection or portal of entry is often evident. • When bacteria are virulent or bacterial exposure is massive, ABE can affect normal valves. • It is usually caused by S. aureus, group A hemolytic streptococci, pneumococci, or gonococci.
  • 17. PROSTHETIC VALVULAR ENDOCARDITIS (PVE) • Develops in 2 to 3% of patients within 1 year after valve replacement and in 0.5%/year thereafter. • It is more common after aortic than after mitral valve replacement and affects mechanical and bioprosthetic valves equally. • Early-onset infections (< 2 months after surgery) are caused mainly by contamination during surgery with antimicrobial-resistant bacteria (eg, S. epidermidis, diphtheroids, coliform bacilli) or by fungi (eg, Candida species, Aspergillus species). • Late-onset infections are caused mainly by contamination with low-virulence organisms during surgery or by transient asymptomatic bacteremias, most often with streptococci; S. epidermidis; diphtheroids; and the fastidious gram-negative bacilli, Haemophilus species, Actinobacillus actinomycetemcomitans, and Cardiobacterium hominis.
  • 18. TYPES OF INFECTIVE ENDOCARDITIS • Endocarditis has evolved into several variations, keeping it near the top of the list of diseases that must not be misdiagnosed or overlooked. • Endocarditis can be broken down into the following categories 1. Native valve endocarditis (NVE), acute and subacute 2. Prosthetic valve endocarditis (PVE), early and late 3. Intravenous drug abuse (IVDA) endocarditis. 4. Other terms commonly used to classify types of IE include pacemaker IE and nosocomial IE (NIE)
  • 19. SIGNS AND SYMPTOMS OF INFECTIVE ENDOCARDITIS • Symptoms and signs vary based on the classification but are usually nonspecific. In Sub acute bacterial endocarditis Initially, symptoms of SBE are vague. • low-grade fever (< 39° C), night sweats, fatigability, malaise, and weight loss. • Chills and arthralgias may occur. Symptoms and signs of valvular insufficiency may be a first clue. • Initially, ≤ 15% of patients have fever or a murmur, but eventually almost all develop both. • Physical examination may be normal or include pallor, fever, change in a preexisting murmur or development of a new regurgitant murmur, and tachycardia.
  • 20. SIGNS AND SYMPTOMS • Retinal emboli can cause round or oval hemorrhagic retinal lesions with small white centers (Roth spots). • Cutaneous manifestations include petechiae (on the upper trunk, conjunctivae, mucous membranes, and distal extremities), painful erythematous subcutaneous nodules on or near the tips of digits (Osler nodes), nontender hemorrhagic macules or papules on the palms or soles (Janeway lesions), and splinter hemorrhages under the nails. • About 35% of patients have central nervous system (CNS) effects, including transient ischemic attacks, stroke, toxic encephalopathy (due to infective microemboli), and, if a mycotic CNS aneurysm ruptures, brain abscess and subarachnoid hemorrhage. • Renal emboli may cause flank pain and, rarely, gross hematuria. • Splenic emboli may cause left upper quadrant pain. Prolonged infection may cause splenomegaly or clubbing of fingers and toes.
  • 21. SIGNS AND SYMPTOMS Acute bacterial endocarditis and prosthetic valvular endocarditis. • Symptoms and signs of acute bacterial endocarditis and prosthetic valvular endocarditis are similar to those of subacute bacterial endocarditis, but the course is more rapid. • Fever is almost always present initially, and patients appear toxic; sometimes septic shock develops. • Heart murmur is present initially in about 50 to 80% and eventually in > 90%. • Rarely, purulent meningitis occurs. Right-sided endocarditis • Septic pulmonary emboli may cause cough, pleuritic chest pain, and sometimes hemoptysis. A murmur of tricuspid regurgitation is typical.
  • 22. OSLER NODES AND JANEWAY LESIONS
  • 23. OSLER NODES , JANEWAY LESIONS AND SPLINTER HEMORRHAGES
  • 25. COMPLICATIONS OF INFECTIVE ENDOCARDITIS • Myocardial infarction, pericarditis, cardiac arrhythmia • Cardiac valvular insufficiency • Congestive heart failure • Sinus of Valsalva aneurysm(an abnormal dilatation of the aortic root located between the aortic valve annulus and the sinotubular junction) • Aortic root or myocardial abscesses • Arterial emboli, infarcts, mycotic aneurysms • Arthritis, myositis • Glomerulonephritis, acute renal failure • Stroke syndromes • Mesenteric or splenic abscess or infarct
  • 26. DIAGNOSIS OF INFECTIVE ENDOCARDITIS • Because symptoms and signs are nonspecific, vary greatly, and may develop insidiously, diagnosis requires a high index of suspicion. • Endocarditis should be suspected in patients with fever and no obvious source of infection, particularly if a heart murmur is present. Diagnosis involves; 1. Blood culture 2. Echocardiography and sometimes other imaging modalities 3. Clinical criteria
  • 27. BLOOD CULTURES • Identification of the organism and its antimicrobial susceptibility is vital to guide treatment. • Three ( 3 ) blood samples for culture (20-mL each) should be obtained, ideally > 6 hours apart (if presentation suggests acute bacterial endocarditis, 2 cultures within the first 1 to 2 hours). • Each set of cultures should be obtained from a separate, fresh venipuncture site. • When endocarditis is present and no prior antibiotic therapy was given, all 3 blood cultures usually are positive because the bacteremia is continuous; at least one culture is positive in 99%. • Premature use of empiric antibiotic therapy should be avoided in patients with acquired or congenital valvular or shunt lesions to avoid culture-negative endocarditis. • If prior antimicrobial therapy was given, blood cultures should still be obtained, but results may be negative.
  • 28. OTHER LABORATORY INVESTIGATIONS • Other than positive blood cultures, there are no specific laboratory findings. • Established infections often cause a normocytic-normochromic anemia, elevated WBC , increased ESR, increased immun IG levels, the presence of circulating immune complexes and RF's, but these findings are not diagnostically helpful. • Urinalysis often shows microscopic hematuria and, occasionally, red blood cell casts, pyuria, or bacteriuria.
  • 29. IMAGING STUDIES • Transthoracic echocardiography (TTE) should be done initially and has sensitivity of 50 to 90% and specificity > 90%. Transesophageal echocardiography (TEE) can reveal vegetations too small to be seen on TTE with a sensitivity of 90 to 100%. • Transesophageal echocardiography should be done when 1. Patients have a prosthetic valve (where TTE sensitivity is limited) 2. Transthoracic echocardiogram is nondiagnostic 3. Diagnosis of infective endocarditis has been established clinically (done to detect perforations, abscesses, and fistulas) NOTE ; Serial TEE enables diagnosis of complications that evolve during treatment, such as increasing vegetation size or abscess formation.
  • 30. IMAGING STUDIES • CT-Scan can fully define paravalvular abscesses and detect mycotic aneurysms. • Positron emission tomography (PET) scanning improves the sensitivity of the modified Duke criteria without compromising specificity. • PET scanning also detects extracardiac infection, such as septic emboli, and is an emerging tool for the diagnosis of endocarditis originating in prosthetic and intracardiac devices. • CT and PET abnormalities are now included as major criteria in the European guidelines. • Routine brain imaging has been proposed because up to 60% of patients have clinically silent lesions. It’s utility for prognosis and management is yet to be defined.
  • 31. DIAGNOSTIC CRITERIA • Infective endocarditis is definitively diagnosed when microorganisms are seen histologically in (or cultured from) endocardial vegetations obtained during cardiac surgery, embolectomy, or autopsy. • Because vegetations are not usually available for examination, there are various clinical criteria for establishing a diagnosis. • They include ; 1. Modified Duke Criteria —with a sensitivity and specificity > 90%, and 2. The European Society of Cardiology (ESC) 2015 modified criteria.
  • 32. MODIFIED DUKES CRITERIA Endocarditis is felt to be present in the following conditions: Direct evidence of endocarditis based upon histological findings (a pathological criterion) Positive Gram stain results or cultures of specimens obtained from surgery or autopsy (a pathological criterion) -2 major clinical criteria -1 major and any 3 minor clinical criteria -5 minor clinical criteria Possible endocarditis’ is defined by 1 major and 1 or 2 minor clinical criteria, OR 3 minor clinical The diagnosis of endocarditis is ‘rejected’ in any of the following cases: - a firm alternate diagnosis is made - clinical manifestations resolve after ≤4 days of antibiotic therapy - no pathological evidence of infective endocarditis is found at surgery or autopsy after antibiotic therapy for ≤4 days - fail to meet criteria for for possible or definite infective endocarditis
  • 33. MODIFIED DUKES CRITERIA [MAJOR AND MINORS]
  • 34. THE EUROPEAN SOCIETY OF CARDIOLOGY CRITERIA • The ESC criteria are similar to the modified Duke criteria but include expanded imaging results as major criteria as follows: 1. Vegetation, abscess, pseudoaneurysm, intracardiac fistula, valvular perforation or aneurysm, or new partial dehiscence of prosthetic valve identified by echocardiography 2. Abnormal activity around a prosthetic valve (implanted > 3 months earlier) detected by PET/CT or single-photon emission computed tomography (SPECT)/CT with radiolabeled leukocytes 3. Paravalvular lesions identified by cardiac • The ESC also differs from the modified Duke minor criteria by specifying that detecting silent vascular phenomena by imaging only is sufficient.
  • 35. MANAGEMENT • IV antibiotics. • Sometimes valve debridement, repair, or replacement • Dental evaluation and treatment. • Removal of potential source of bacteremia. • Withholding anticoagulation in patients with cerebral embolism
  • 36. UGANDA CLINICAL GUIDELINES (UCG) ANTIBIOTICS FOR INFECTIVE ENDOCARDITIS Initial empirical antibiotic therapy • Benzylpenicillin 5 MU IV every 6 hours for 4 weeks • Plus gentamicin 1 mg/kg IV every 8 hours for 2 weeks. If staphylococcus suspected, (acute onset) add: • Cloxacillin IV 3 g every 6 hours. If MRSA (Multi-Resistant Staphylococcus aureus). • Vancomycin 500 mg IV every 6 hours for 6 weeks.
  • 37. PROGNOSIS Overall, the in-hospital mortality rate for endocarditis is 15 to 20%, with a 1-year mortality rate approaching 40%. Untreated, infective endocarditis is always fatal. Even with treatment, death is more likely and the prognosis is generally poorer for older people and people who have • Infection with resistant organisms • An underlying disorder • A long delay in treatment • Aortic valve or multiple valve involvement • Large vegetations • Polymicrobial bacteremia • Prosthetic valve infections • Mycotic aneurysms • Valve ring abscess • Major embolic events
  • 38. PROGNOSIS • Septic shock is more likely in patients with diabetes, acute kidney injury, S. aureus infection, vegetation size > 15 mm, and signs of persistent infection. • The mortality rate for viridans streptococcal endocarditis without major complications is < 10% but is virtually 100% for Aspergillus endocarditis after prosthetic valve surgery. • The prognosis is better with right-sided than left-sided endocarditis because tricuspid valve dysfunction is tolerated better, systemic emboli are absent, and right-sided S. aureus endocarditis responds better to antimicrobial therapy.
  • 39. PREVENTION OF INFECTIVE ENDOCARDITIS • Preventive dental examination and therapy before surgery to repair heart valves or congenital heart lesions is recommended. • Measures to reduce health care–acquired bacteremia aim to curb the rising incidence of iatrogenic bacteremia and subsequent endocarditis are also recommended. • During implantation of prosthetic devices, prophylaxis often involves use of amoxicillin/clavulanic acid. • Dental and cutaneous hygiene is recommended for the general population but particularly for patients at intermediate risk (those with native valve disease) and high-risk.
  • 40. PREVENTION OF INFECTIVE ENDOCARDITIS. • Prosthetic heart valves, including transcatheter implanted prostheses • Prosthetic material used for heart valve repair (eg, annuloplasty rings, chords) • Previous infective endocarditis • Certain congenital heart diseases (CHD): Unrepaired cyanotic CHD (including palliative shunts and conduits), completely repaired CHD during the first 6 mo after surgery if prosthetic material or device was used, repaired CHD that has residual defects at or adjacent to the site of repair • Heart transplant recipients with valvulopathy
  • 41. LIBAN SACKS ENDOCARDITIS • Non infection related endocarditis associated with Systemic lupus erytheramatosus • Antigen-antibody complexes. • Affects mainly the mitral valve, but can affect both atrial and ventricular endocardium.
  • 42. THANK YOU NOTE AND REFERENCES Thank you for paying attention, may you be able to prevent infective endocarditis and efficiently manage patient presenting with the condition. References 1.Davidsons 2. Uganda clinical guidelines (UCG) 3. Merck manuals (MSD) 2022.